Search CSTL
CASTLE BIOSCIENCES INC
Nasdaq · CIK 1447362
Last close35.56
Daily change+0.31 (0.87%)
10 Years gain+66.17%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CSTL · STANDARD
SIC 8071 · Services-Medical Laboratories · Fiscal year end 1231
Fundamental
59.0Momentum
39.3Acceleration
39.6Confidence
91.0Annual Revenue8
Quarterly Revenue31
Annual CFO8
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth19.9 / 25
Quality12.9 / 25
Capital Efficiency5.9 / 20
Balance Sheet15.0 / 15
Shareholder Economics2.4 / 10
Forward Indicators0.0 / 5
Signals
Net debt reductionNet debt declined versus the comparison period.
Warnings
Inventory anomaly · MEDIUMInventory growth is materially above revenue growth.
Gross margin compression · MEDIUMGross margin compressed by 4.502 percentage points.
Operating margin compression · MEDIUMOperating margin compressed by 2.1428 percentage points.
Key Metrics
Revenue Growth TTM6.8%OK
Revenue CAGR 3Y35.94%OK
Gross Margin77.4%OK
Operating Margin-9.13%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-10.75%OK
Incremental Operating Margin 3Y6.67%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y6.26%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $344.23M | $273.20M | -$42.81M | $64.35M | $28.33M | 79.37% | -12.44% | 8.23% | -19.1% | 28.99M |
| 2025 FY Dec 31, 2024 | $332.07M | $271.86M | $8.67M | $64.87M | $36.54M | 81.87% | 2.61% | 11% | 4.27% | 29.26M |
| 2025 FY Dec 31, 2023 | $219.79M | $174.81M | -$67.98M | -$5.63M | -$19.25M | 79.53% | -30.93% | -8.76% | -37.2% | 26.8M |
| 2024 FY Dec 31, 2022 | $137.04M | $105.03M | -$72.86M | -$41.66M | -$47.29M | 76.64% | -53.16% | -34.51% | -51.7% | 26.05M |
| 2022 FY Dec 31, 2021 | $94.09M | $78.26M | -$40.08M | -$18.98M | -$22.47M | 83.18% | -42.6% | -23.88% | -72% | 25.14M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $356.46M | sum latest 4 fiscal quarters Revenue | OK | 0001628280-26-051052, 0001628280-25-048254 |
| Revenue Growth TTM | 6.8% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001628280-26-051052, 0001628280-25-048254 |
| Revenue CAGR 3Y | 35.94% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012272 |
| Revenue CAGR 5Y | 40.6% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001628280-26-012272 |
| Gross Profit CAGR 3Y | 37.53% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001628280-26-012272 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001628280-26-051052, 0001628280-25-048254 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 77.4% | Gross Profit / Revenue | OK | 0001628280-26-051052, 0001628280-25-048254 |
| Operating Margin | -9.13% | Operating Income / Revenue | OK | 0001628280-26-051052, 0001628280-25-048254 |
| ROIC | -10.75% | NOPAT / Average Invested Capital | OK | 0001628280-26-051052, 0001628280-25-048254 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001628280-26-051052 |
| Current Ratio | 6.04x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 26.48x | (Cash + Short-term Investments) / Total Debt | OK | 0001628280-26-051052 |
| Revenue per Diluted Share | $11.73 | Revenue / Diluted Shares | OK | 0001628280-26-051052, 0001628280-25-048254 |